Modifi Biosciences, a pioneering biotech company based in the heart of New Haven, CT, has successfully raised $10.7 million to advance its groundbreaking oncology therapeutics platform. Founded by a team of esteemed scientists and experienced entrepreneurs, including Seth Herzon from Yale University and Ranjit Bindra from the Yale School of Medicine, Modifi Bio is on a mission to revolutionize cancer treatment through an innovative approach that targets DNA defects in cancer cells while sparing healthy tissue. Unlike traditional therapies that often focus on protein targets, Modifi Bio’s novel small molecules directly engage with tumor DNA, rendering critical repair mechanisms in cancer cells irreparable. This transformative concept has garnered strong validation in preclinical studies across various tumor types, showcasing its vast potential to disrupt conventional oncology drug development.
The newly acquired funding will be instrumental in accelerating Modifi Bio’s research and development efforts, enabling the team to expand its clinical trials and refine its therapeutic candidates. Positioned strategically within the Elm City BioScience Center, a premier biotechnology facility adjacent to Yale, Modifi Bio is well-equipped to capitalize on the collaborative ecosystem of researchers and institutes in the region. With their commitment to improving patient outcomes and a robust foundation of scientific expertise, Modifi Biosciences is poised to make significant strides in the fight against cancer, offering hope to patients worldwide. As the company embarks on this exciting phase of growth, stakeholders and cancer advocates alike are eagerly watching their journey towards groundbreaking oncology solutions.
